Opinion|Videos|December 10, 2024
Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Rebyota's FDA approval was based on clinical trial data showing significant reduction in CDI recurrence rates compared to placebo.
- The pivotal trial was a randomized, double-blind, placebo-controlled study demonstrating Rebyota's efficacy in recurrent CDI.
The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile infections.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the key data that led to the FDA approval of Rebyota for recurrent C difficile infection?
- Who are the target patient populations for Rebyota?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
2
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
3
Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis
4
CKD Caregiving Drives Social Isolation, Loneliness
5